Dr. Patrick Lawless was working as a biopharmaceutical research scientist in 2007 when he witnessed Barbaro’s tragic breakdown in the Preakness Stakes. With the entire nation, he followed the courageous battle waged by this horse and his caretakers until he finally succumbed to the tragedy of laminitis. At the same time, there was a growing body of research on a compound called resveratrol that showed promising results in the management of chronic inflammation and metabolic disease. Pat realized that there was an opportunity to help horses suffering from laminitis and other health conditions that shared many of the same features.
As a result, Equithrive was created in 2008. Initial testing of this resveratrol formulation at Churchill Downs resulted in veterinarians and trainers reporting significant improvement in horses suffering from various inflammatory disorders and joint soreness. In 2009 the initial formula called “Equithrive Joint” underwent testing at the Gluck Equine Research Center, which confirmed that the product significantly reduced gene-linked release of inflammatory mediators in the horse. Veterinarians across the United States now routinely prescribe Equithrive to manage chronic inflammation and soreness in both equine athletes and older horses.
Equithrive is the pioneer in equine resveratrol therapy and is the industry leader in gene expression therapy for horses, with an ongoing focus on the management of inflammation, laminitis, and metabolic syndrome.
Due to the positive response and documented health benefits of Equithrive, we are pleased to announce the December 2010 release of “Petthrive™”, a resveratrol-based product that targets chronic inflammatory conditions in small animals.
Pat enjoys spending time with his daughter Sage and has many interests including photography, white water kayaking, and triathlon training. He has a PhD from the University of Kentucky with a special emphasis in biopharmaceutical research.